Literature DB >> 15466974

STK15 polymorphisms and association with risk of invasive ovarian cancer.

Richard A Dicioccio1, Honglin Song, Christy Waterfall, Makoto T Kimura, Hiroki Nagase, Valerie McGuire, Estrid Hogdall, Mitul N Shah, Robert N Luben, Douglas F Easton, Ian J Jacobs, Bruce A J Ponder, Alice S Whittemore, Simon A Gayther, Paul D P Pharoah, Susan Kruger-Kjaer.   

Abstract

STK15 is a putative oncogene that codes for a centrosome-associated, serine/threonine kinase, the normal function of which is to ensure accurate segregation of chromosomes during mitosis. Amplification of STK15 has been reported in ovarian tumors, suggesting a role in ovarian cancer pathology. STK15 is polymorphic with two single nucleotide substitutions (449t/a and 527g/a) in evolutionarily conserved regions causing amino acid changes (F31I and V57I). Two other nucleotide substitutions (287c/g and 1891g/c) of unknown significance are in 5' and 3' untranslated regions (UTR), respectively. To learn more about the involvement of STK15 in ovarian cancer, we genotyped and haplotyped these polymorphisms in three population-based ovarian cancer case-control studies from the United Kingdom, United States, and Denmark with 1,821 combined cases and 2,467 combined controls and calculated risks for developing ovarian cancer. Genotypes of individual polymorphisms in control groups of the United Kingdom, United States, and Denmark conformed to Hardy-Weinberg equilibrium. In combined cases and combined controls, rare allele frequencies were 0.23 and 0.21 for I31, 0.16 and 0.17 for I57, 0.08 and 0.07 for 5' UTR g, and 0.25 and 0.24 for 3' UTR c, respectively. Using FF common homozygotes of F31I as comparator, there was increased ovarian cancer risk to FI heterozygotes (odds ratio, 1.18; 95% confidence interval, 1.01-1.36), II homozygotes (odds ratio, 1.25; 95% confidence interval, 0.89-1.75), and I31 allele carriers (odds ratio, 1.17; 95% confidence interval, 1.02-1.35) in the combined group data. For either V57I, 5' UTR C/G, or 3' UTR G/C, all genotypic ovarian cancer risks were essentially in unity relative to their respective common homozygotes, VV, cc, or gg. Haplotype analysis of combined group data revealed seven haplotypes with frequencies between 0.02 and 0.5, with c-F-V-g the most common. None of the haplotype-specific risks significantly differed from unity relative to c-F-V-g. These results suggest a model of dominant inheritance of ovarian cancer risk by the I31 allele of F31I and that the I31 allele may be a common ovarian cancer susceptibility allele of low penetrance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466974

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  21 in total

1.  Association between the STK15 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jun Qin; Xiao-Feng He; Wu Wei; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Hui-Qiang Si
Journal:  Mol Genet Genomics       Date:  2014-08-26       Impact factor: 3.291

2.  AURKA Phe31Ile polymorphism interacted with use of alcohol, betel quid, and cigarettes at multiplicative risk of oral cancer occurrence.

Authors:  Chi-Pin Lee; Shang-Lun Chiang; Chien-Hung Lee; Yi-Shan Tsai; Zhi-Hong Wang; Chun-Hung Hua; Yuan-Chien Chen; Eing-Mei Tsai; Ying-Chin Ko
Journal:  Clin Oral Investig       Date:  2015-02-21       Impact factor: 3.573

3.  A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).

Authors:  Yael P Mossé; Elizabeth Fox; David T Teachey; Joel M Reid; Stephanie L Safgren; Hernan Carol; Richard B Lock; Peter J Houghton; Malcolm A Smith; David Hall; Donald A Barkauskas; Mark Krailo; Stephan D Voss; Stacey L Berg; Susan M Blaney; Brenda J Weigel
Journal:  Clin Cancer Res       Date:  2019-02-18       Impact factor: 12.531

4.  Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk.

Authors:  Makoto T Kimura; Takahiro Mori; Jeffrey Conroy; Norma J Nowak; Susumu Satomi; Katsuyuki Tamai; Hiroki Nagase
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

5.  Role of DNA repair and cell cycle control genes in ovarian cancer susceptibility.

Authors:  Faten Zahran Mohamed; Yousry Mostafa Hussien; Mohamad Mohamad AlBakry; Randa H Mohamed; Noha Mohamed Said
Journal:  Mol Biol Rep       Date:  2013-01-01       Impact factor: 2.316

6.  Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.

Authors:  Noa Matarasso; Anat Bar-Shira; Uri Rozovski; Serena Rosner; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

7.  Consortium analysis of 7 candidate SNPs for ovarian cancer.

Authors:  Susan J Ramus; Robert A Vierkant; Sharon E Johnatty; Malcolm C Pike; David J Van Den Berg; Anna H Wu; Celeste Leigh Pearce; Usha Menon; Aleksandra Gentry-Maharaj; Simon A Gayther; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Honglin Song; Douglas F Easton; Paul D P Pharoah; Montserrat Garcia-Closas; Stephen Chanock; Jolanta Lissowska; Louise Brinton; Kathryn L Terry; Daniel W Cramer; Shelley S Tworoger; Susan E Hankinson; Andrew Berchuck; Patricia G Moorman; Joellen M Schildkraut; Julie M Cunningham; Mark Liebow; Susanne Krüger Kjaer; Estrid Hogdall; Claus Hogdall; Jan Blaakaer; Roberta B Ness; Kirsten B Moysich; Robert P Edwards; Michael E Carney; Galina Lurie; Marc T Goodman; Shan Wang-Gohrke; Silke Kropp; Jenny Chang-Claude; Penelope M Webb; Xiaoqing Chen; Jonathan Beesley; Georgia Chenevix-Trench; Ellen L Goode
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

8.  Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.

Authors:  L Quaye; H Song; S J Ramus; A Gentry-Maharaj; E Høgdall; R A DiCioccio; V McGuire; A H Wu; D J Van Den Berg; M C Pike; E Wozniak; J A Doherty; M A Rossing; R B Ness; K B Moysich; C Høgdall; J Blaakaer; D F Easton; B A J Ponder; I J Jacobs; U Menon; A S Whittemore; S Krüger-Kjaer; C L Pearce; P D P Pharoah; S A Gayther
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

9.  Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma.

Authors:  Christopher Ricketts; Maurice P Zeegers; Jan Lubinski; Eamonn R Maher
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

10.  Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.

Authors:  J M Cunningham; R A Vierkant; T A Sellers; C Phelan; D N Rider; M Liebow; J Schildkraut; A Berchuck; F J Couch; X Wang; B L Fridley; A Gentry-Maharaj; U Menon; E Hogdall; S Kjaer; A Whittemore; R DiCioccio; H Song; S A Gayther; S J Ramus; P D P Pharaoh; E L Goode
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.